TD Cowen on Dianthus (DNTH): 'the favorable economics of the deal will not impact prior guidance of cash runway into 2028'
Tweet Send to a Friend
TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments "Today, Dianthus entered into ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
